Annual SG&A Expense Ratio Comparison for AstraZeneca, Pfizer, and GlaxoSmithKline

Comparing SG&A expense ratios of AstraZeneca, Pfizer, and GSK over the years.

__timestampAstraZeneca PLCGSK plcPfizer Inc.
Tuesday, January 1, 19850
Wednesday, January 1, 198600
Thursday, January 1, 198700
Friday, January 1, 198800
Sunday, January 1, 198900
Monday, January 1, 1990000
Tuesday, January 1, 1991000
Wednesday, January 1, 1992000
Friday, January 1, 1993000
Saturday, January 1, 199400.67039478359264490.5301341576805574
Sunday, January 1, 1995000.5285788412796615
Monday, January 1, 1996000.5351140987086502
Wednesday, January 1, 1997000.3963531669865643
Thursday, January 1, 1998000.4111045481393975
Friday, January 1, 1999000.3919402616637867
Saturday, January 1, 2000000.3868938932846419
Monday, January 1, 200100.363654645394825060.3502588424935677
Tuesday, January 1, 20020.33619194923754610.37907788044503110
Wednesday, January 1, 20030.363732824022494570.354321160393638370
Thursday, January 1, 20040.38588630635676280.36030221154808370
Saturday, January 1, 20050.37185803757828810.33471837488457990
Sunday, January 1, 20060.35210576015108590.31237751302475780
Monday, January 1, 20070.35901079197537130.300383474203204770
Tuesday, January 1, 20080.354545742223347340.3143889618922470
Thursday, January 1, 20090.345445677356419960.338127467569091960
Friday, January 1, 20100.31395593495446210.459742180896027030
Saturday, January 1, 20110.3322616176952160.32226968999890460
Sunday, January 1, 20120.35173202731205090.330634482236767450.2342250703556776
Tuesday, January 1, 20130.47473843880051340.319939634031314870.22012639578163773
Wednesday, January 1, 20140.498179727917225530.35842823611231850.2216913617578873
Thursday, January 1, 20150.44973288003885380.38590477782886760.23968803095125996
Friday, January 1, 20160.409225284757847140.33583133134927750.22029759200363472
Sunday, January 1, 20170.455508568884932130.320413436692506440.2223575533817988
Monday, January 1, 201800.321696246065993950.21911756482189126
Tuesday, January 1, 20190.47908464566929130.33779700183681930.23285024154589373
Wednesday, January 1, 202000.33596293146426580.23420349336642168
Friday, January 1, 202100.32171542475230110.1316676508217695
Saturday, January 1, 202200.28549993179648070.10841223960928935
Sunday, January 1, 202300.30945001318913220.18411515317286653
Loading chart...

Unleashing the power of data

Annual SG&A Expense Ratio Comparison for Leading Pharmaceutical Giants

A Historical Perspective on SG&A Expense Ratios

In the competitive world of pharmaceuticals, managing Sales, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. This analysis delves into the SG&A expense ratios of three industry titans: AstraZeneca, Pfizer, and GlaxoSmithKline (GSK), over the past few decades.

AstraZeneca: A Steady Climb

AstraZeneca's SG&A to revenue ratio has shown a consistent pattern since the early 2000s. Notably, in 2004, the ratio peaked at approximately 38.6%, reflecting significant investment in administrative and sales functions. This trend underscores AstraZeneca's strategic focus on expanding its market reach and operational capabilities.

Pfizer: A Balanced Approach

Pfizer, known for its blockbuster drugs, has maintained a relatively balanced SG&A expense ratio. In the mid-1990s, the ratio hovered around 53%, indicating substantial spending on sales and administrative activities. However, by the early 2000s, Pfizer managed to reduce this ratio to around 35%, showcasing its efficiency in managing operational costs.

GSK: A High-Spending Strategy

GSK's SG&A expense ratio has been notably high, peaking at 67% in 1994. This high ratio reflects GSK's aggressive investment in sales and administrative functions to bolster its market presence. Despite fluctuations, GSK has consistently allocated a significant portion of its revenue to SG&A expenses, highlighting its commitment to maintaining a robust operational framework.

Conclusion

The SG&A expense ratios of these pharmaceutical giants reveal their strategic priorities and operational efficiencies. While AstraZeneca and Pfizer have shown a trend towards optimizing their SG&A expenses, GSK's high ratios indicate a continued focus on aggressive market expansion. Understanding these trends provides valuable insights into the financial strategies of these leading companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
15 Sept 2024